Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315 · see citing works

The Effect of Spironolactone on Morbidity and Mortality in Patients with Severe Heart Failure

Pitt, B., Zannad, F., Remme, W. J., Cody, R., Castaigne, A., Perez, A., Palensky, J., & Wittes, J. (1999) · New England Journal of Medicine · doi:10.1056/nejm199909023411001 · Cited by 9,214 · see citing works

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38

(1998) · BMJ · doi:10.1136/bmj.317.7160.703 · Cited by 6,683 · see citing works

Effects of intensive blood-pressure control in type 2 diabetes mellitus

(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598 · see citing works

Effect of a multifactorial intervention on mortality in type 2 diabetes

Gæde, P., Lund-Andersen, H., Parving, H.-H., & Pedersen, O. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0706245 · Cited by 3,489 · see citing works

Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial

Patel, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61303-8 · Cited by 2,054 · see citing works

Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials

Wang, R., Lagakos, S. W., Ware, J. H., Hunter, D. J., & Drazen, J. M. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr077003 · Cited by 1,445 · see citing works

Adaptation of the distal convoluted tubule of the rat. Structural and functional effects of dietary salt intake and chronic diuretic infusion.

Ellison, D. H., Velázquez, H., & Wright, F. S. (1989) · Journal of Clinical Investigation · doi:10.1172/jci113847 · Cited by 294 · see citing works

Effects of Mineralocorticoid Receptor Antagonists on the Risk of Sudden Cardiac Death in Patients With Left Ventricular Systolic Dysfunction

Bapoje, S. R., Bahia, A., Hokanson, J. E., Peterson, P. N., Heidenreich, P. A., Lindenfeld, J. M., Allen, L. A., & Masoudi, F. A. (2013) · Circulation Heart Failure · doi:10.1161/circheartfailure.112.000003 · Cited by 45 · see citing works

Type 2 diabetes

Chatterjee, S., Khunti, K., & Davies, M. J. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30058-2 · Cited by 2,577 · see citing works

Genetics of diabetes mellitus and diabetes complications

Cole, J. B., & Florez, J. C. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0278-5 · Cited by 1,797 · see citing works

Insulin resistance and hyperinsulinaemia in diabetic cardiomyopathy

Jia, G., DeMarco, V. G., & Sowers, J. R. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.216 · Cited by 954 · see citing works

Effects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial

Margulies, K. B., Hernandez, A. F., Redfield, M. M., Givertz, M. M., Oliveira, G. H., Cole, R., Mann, D. L., Whellan, D. J., Kiernan, M. S., Felker, G. M., et al. (2016) · JAMA · doi:10.1001/jama.2016.10260 · Cited by 706 · see citing works

Empagliflozin rescues diabetic myocardial microvascular injury via AMPK-mediated inhibition of mitochondrial fission

Zhou, H., Wang, S., Zhu, P., Hu, S., Chen, Y., & Ren, J. (2018) · Redox Biology · doi:10.1016/j.redox.2017.12.019 · Cited by 550 · see citing works

2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure

Ponikowski, P. P., Voors, A. A., Anker, S. D., Bueno, H., Cleland, J. G. F., Coats, A. J. S., Falk, V., González‐Juanatey, J. R., Harjola, V., Jankowska, E. A., et al. (2016) · Kardiologia Polska · doi:10.5603/kp.2016.0141 · Cited by 450 · see citing works

Updated Cardiovascular Prevention Guideline of the Brazilian Society of Cardiology - 2019

Précoma, D. B., de Oliveira, G. M. M., Simão, A. F. L., Dutra, Ó. P., Coelho-Filho, O. R., Izar, M. C. D. O., Póvoa, R., Giuliano, I. D. C. B., Filho, A. C. D. A., Machado, C. A., et al. (2019) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20190204 · Cited by 469 · see citing works

Empagliflozin in Heart Failure

Griffin, M. D., Rao, V. S., Ivey-Miranda, J. B., Fleming, J. H., Mahoney, D., Maulion, C., Suda, N., Siwakoti, K., Ahmad, T., Jacoby, D. L., et al. (2020) · Circulation · doi:10.1161/circulationaha.120.045691 · Cited by 421 · see citing works

Association of bariatric surgery vs medical obesity treatment with long-term medical complications and obesity-related comorbidities

Jakobsen, G. S., Småstuen, M. C., Sandbu, R., Nordstrand, N., Hofsø, D., Lindberg, M., Hertel, J. K., & Hjelmesæth, J. (2018) · JAMA · doi:10.1001/jama.2017.21055 · Cited by 358 · see citing works

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction: Results of DAPA-HF

Jhund, P. S., Solomon, S. D., Docherty, K. F., Heerspink, H. J. L., Anand, I. S., Böhm, M., Chopra, V., de Boer, R. A., Desai, A. S., Ge, J., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050391 · Cited by 307 · see citing works

Neuroprotective effect of SGLT2 inhibitors.

Pawlos, A., Broncel, M., Woźniak, E., & Gorzelak-Pabiś, P. (2021) · Molecules · doi:10.3390/molecules26237213 · Cited by 304 · see citing works

Coronary heart disease risk: Low-density lipoprotein and beyond

Shaya, G. E., Leucker, T. M., Jones, S. R., Martin, S. S., & Toth, P. P. (2021) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2021.04.002 · Cited by 243 · see citing works

The Canagliflozin and Renal Endpoints in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) study rationale, design, and baseline characteristics

Jardine, M. J., Mahaffey, K. W., Neal, B., Agarwal, R., Bakris, G. L., Brenner, B. M., Bull, S., Cannon, C. P., Charytan, D. M., de Zeeuw, D., et al. (2017) · American Journal of Nephrology · doi:10.1159/000484633 · Cited by 234 · see citing works

Empagliflozin for Type 2 Diabetes Mellitus: An Overview of Phase 3 Clinical Trials

Levine, M. J. (2016) · Current Diabetes Reviews · doi:10.2174/1573399812666160613113556 · Cited by 235 · see citing works

7. Approaches to Glycemic Treatment

American Diabetes Association (2015) · Diabetes Care · doi:10.2337/dc16-s010 · Cited by 225 · see citing works

Empagliflozin attenuates the renal tubular ferroptosis in diabetic kidney disease through AMPK/NRF2 pathway

Lu, Q., Yang, L.-J., Xiao, J., Liu, Q., Ni, L., Hu, J.-W., Yu, H. J., Wu, X., & Zhang, B. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.12.088 · Cited by 214 · see citing works

2024 Clinical practice guidelines for Chronic heart failure

Galyavich, A. S., Tereshchenko, S. N., Uskach, T. M., Ageev, F. T., Aronov, D. M., Arutyunov, G. P., Begrambekova, Y. L., Belenkov, Y. N., Boytsov, S. A., Bubnova, M. G., et al. (2024) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2024-6162 · Cited by 251 · see citing works

Heart failure in patients with kidney disease

Tuegel, C., & Bansal, N. (2017) · Heart · doi:10.1136/heartjnl-2016-310794 · Cited by 195 · see citing works

Sex- and Gender-Based Pharmacological Response to Drugs

Mauvais‐Jarvis, F., Berthold, H. K., Campesi, I., Carrero, J. J., Dhakal, S., Franconi, F., Gouni‐Berthold, I., Heiman, M. L., Kautzky‐Willer, A., Klein, S. L., et al. (2021) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000206 · Cited by 194 · see citing works

Combination therapy for non-alcoholic steatohepatitis: rationale, opportunities and challenges

Dufour, J.-F., Caussy, C., & Loomba, R. (2020) · Gut · doi:10.1136/gutjnl-2019-319104 · Cited by 193 · see citing works

Glycemic control by the SGLT2 inhibitor empagliflozin decreases aortic stiffness, renal resistivity index and kidney injury

Aroor, A. R., Das, N. A., Carpenter, A. J., Habibi, J., Jia, G., Ramirez‐Perez, F. I., Martinez‐Lemus, L. A., Manrique‐Acevedo, C., Hayden, M. R., Duta, C., et al. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0750-8 · Cited by 179 · see citing works

Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy

Byrne, N. J., Rajasekaran, N. S., Abel, E. D., & Bugger, H. (2021) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2021.03.046 · Cited by 175 · see citing works

Epidemiology, Pathophysiology, Diagnosis and Treatment of Heart Failure in Diabetes

Park, J. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0282 · Cited by 179 · see citing works

Empagliflozin reduces body weight and indices of adipose distribution in patients with type 2 diabetes mellitus

Neeland, I. J., McGuire, D. K., Chilton, R., Crowe, S., Lund, S. S., Woerle, H. J., Broedl, U. C., & Johansen, O. E. (2016) · Diabetes and Vascular Disease Research · doi:10.1177/1479164115616901 · Cited by 168 · see citing works

Sodium-dependent glucose transporters (SGLT) in human ischemic heart: A new potential pharmacological target

Franco, A. D., Cantini, G., Tani, A., Coppini, R., Zecchi‐Orlandini, S., Raimondi, L., Luconi, M., & Mannucci, E. (2017) · International Journal of Cardiology · doi:10.1016/j.ijcard.2017.05.032 · Cited by 164 · see citing works

Impact of sodium glucose cotransporter 2 (SGLT2) inhibitors on atherosclerosis: From pharmacology to pre-clinical and clinical therapeutics

Liu, Z., Ma, X., Ilyas, I., Zheng, X., Luo, S., Little, P. J., Kamato, D., Sahebkar, A., Wu, W., Weng, J., et al. (2021) · Theranostics · doi:10.7150/thno.54498 · Cited by 155 · see citing works

Effects of Finerenone Combined with Empagliflozin in a Model of Hypertension-Induced End-Organ Damage

Kolkhof, P., Hartmann, E., Freyberger, A., Pavkovic, M., Mathar, I., Sandner, P., Droebner, K., Joseph, A., Hüser, J., & Eitner, F. (2021) · American Journal of Nephrology · doi:10.1159/000516213 · Cited by 143 · see citing works

Left Ventricular Remodeling after Myocardial Infarction: From Physiopathology to Treatment

Leancă, S. A., Crișu, D., Petriş, A. O., Afrăsânie, I., Genes, A., Costache, A. D., Tesloianu, D. N., & Costache, I. I. (2022) · Life · doi:10.3390/life12081111 · Cited by 152 · see citing works

Anti-inflammatory role of SGLT2 inhibitors as part of their anti-atherosclerotic activity: Data from basic science and clinical trials

Scisciola, L., Cataldo, V., Taktaz, F., Fontanella, R. A., Pesapane, A., Ghosh, P., Franzese, M., Puocci, A., Angelis, A. D., Sportiello, L., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1008922 · Cited by 132 · see citing works

Empagliflozin Attenuates Hyperuricemia by Upregulation of ABCG2 via AMPK/AKT/CREB Signaling Pathway in Type 2 Diabetic Mice

Lu, Y., Chang, Y., Li, T., Han, F., Li, C., Li, X., Xue, M., Cheng, Y., Meng, Z., Han, Z., et al. (2020) · International Journal of Biological Sciences · doi:10.7150/ijbs.33007 · Cited by 129 · see citing works

RSSDI clinical practice recommendations for the management of type 2 diabetes mellitus 2017

Bajaj, S. (2018) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-018-0604-7 · Cited by 129 · see citing works

2019 Guidelines on the management of diabetic patients. A position of Diabetes Poland

Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Budzynski, A. Z., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., Dziedzic, T., Franek, E., et al. (2019) · Clinical Diabetology · doi:10.5603/dk.2019.0001 · Cited by 126 · see citing works

Empagliflozin ameliorates endothelial dysfunction and suppresses atherogenesis in diabetic apolipoprotein E-deficient mice

Ganbaatar, B., Fukuda, D., Shinohara, M., Yagi, S., Kusunose, K., Yamada, H., Soeki, T., Hirata, K., & Sata, M. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173040 · Cited by 121 · see citing works

Empagliflozin improves diabetic renal tubular injury by alleviating mitochondrial fission via AMPK/SP1/PGAM5 pathway

Liu, X., Xu, C., Xu, L., Li, X., Sun, H., Xue, M., Li, T., Yu, X., Sun, B., & Chen, L. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154334 · Cited by 121 · see citing works

Type 2 Diabetes and Heart Failure: Challenges and Solutions

Thomas, M. C. (2016) · Current Cardiology Reviews · doi:10.2174/1573403x12666160606120254 · Cited by 119 · see citing works

Changing use of antidiabetic drugs in the UK: trends in prescribing 2000–2017

Wilkinson, S., Douglas, I., Stirnadel-Farrant, H. A., Fogarty, D. G., Pokrajac, A., Smeeth, L. L., & Tomlinson, L. A. (2018) · BMJ Open · doi:10.1136/bmjopen-2018-022768 · Cited by 117 · see citing works

Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies

Thrasher, J. R. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.009 · Cited by 113 · see citing works

The SGLT2 inhibitor Empagliflozin attenuates interleukin-17A-induced human aortic smooth muscle cell proliferation and migration by targeting TRAF3IP2/ROS/NLRP3/Caspase-1-dependent IL-1β and IL-18 secretion

Sukhanov, S., Higashi, Y., Yoshida, T., Mummidi, S., Aroor, A. R., Russell, J. J., Bender, S. B., DeMarco, V. G., & Chandrasekar, B. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2020.109825 · Cited by 113 · see citing works

Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies

Thrasher, J. R. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.004 · Cited by 112 · see citing works

Empagliflozin reduces high glucose-induced oxidative stress and miR-21-dependent TRAF3IP2 induction and RECK suppression, and inhibits human renal proximal tubular epithelial cell migration and epithelial-to-mesenchymal transition

Das, N. A., Carpenter, A. J., Belenchia, A. M., Aroor, A. R., Noda, M., Siebenlist, U. K., Chandrasekar, B., & DeMarco, V. G. (2019) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109506 · Cited by 107 · see citing works

Sodium glucose cotransporter 2 inhibition in the diabetic kidney

Novikov, A., & Vallon, V. (2015) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000187 · Cited by 106 · see citing works

Therapeutic Manipulation of Myocardial Metabolism

Honka, H., Solis‐Herrera, C., Triplitt, C. L., Norton, L., Butler, J., & DeFronzo, R. A. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.02.057 · Cited by 98 · see citing works

Treatment of type 2 diabetes mellitus in the elderly

Yakaryılmaz, F. D., & Öztürk, Z. A. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.278 · Cited by 104 · see citing works

A comparison of effects of DPP-4 inhibitor and SGLT2 inhibitor on lipid profile in patients with type 2 diabetes

Cha, S., Park, Y., Yun, J., Lim, T., Song, K., Yoo, K., Ahn, Y., & Ko, S. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0443-4 · Cited by 100 · see citing works

Albuminuria, serum creatinine, and estimated glomerular filtration rate as predictors of cardio-renal outcomes in patients with type 2 diabetes mellitus and kidney disease: a systematic literature review

Norris, K. C., Smoyer, K. E., Rolland, C., der Vaart, J. V., & Grubb, E. (2018) · BMC Nephrology · doi:10.1186/s12882-018-0821-9 · Cited by 100 · see citing works

Genital Infections with Sodium Glucose Cotransporter-2 Inhibitors: Occurrence and Management in Patients with Type 2 Diabetes Mellitus

Unnikrishnan, A., Kalra, S., Purandare, V. B., & Vasnawala, H. (2018) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/ijem.ijem_159_17 · Cited by 100 · see citing works

Dipeptidyl Peptidase 4 Inhibition Stimulates Distal Tubular Natriuresis and Increases in Circulating SDF-1α1-67 in Patients With Type 2 Diabetes

Lovshin, J. A., Rajasekeran, H., Lytvyn, Y., Lovblom, L. E., Khan, S., Alemu, R. Z., Locke, A., LAI, V. S., He, H., Hittle, L. R., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0061 · Cited by 99 · see citing works

Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms

Staels, B. (2017) · The American Journal of Medicine · doi:10.1016/j.amjmed.2017.04.009 · Cited by 92 · see citing works

Thrombo-Inflammation in Cardiovascular Disease: An Expert Consensus Document from the Third Maastricht Consensus Conference on Thrombosis

D’Alessandro, E., Becker, C., Bergmeier, W., Bode, C., Bourne, J. H., Brown, H. C., Buller, H. R., ten Cate‐Hoek, A. J., ten Cate, V., van Cauteren, Y. J. M., et al. (2020) · Thrombosis and Haemostasis · doi:10.1055/s-0040-1708035 · Cited by 90 · see citing works

Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary

Mascolo, A., Napoli, R. D., Balzano, N., Cappetta, D., Urbanek, K., Angelis, A. D., Scisciola, L., Meo, I. D., Sullo, M. G., Rafaniello, C., et al. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1010693 · Cited by 89 · see citing works

Reductions in Mean 24‐Hour Ambulatory Blood Pressure After 6‐Week Treatment With Canagliflozin in Patients With Type 2 Diabetes Mellitus and Hypertension

Townsend, R. R., Machin, I., Ren, J., Trujillo, A., Kawaguchi, M., Vijapurkar, U., Damaraju, C. V., & Pfeifer, M. (2016) · The Journal of Clinical Hypertension · doi:10.1111/jch.12747 · Cited by 85 · see citing works

Efficacy and safety of American ginseng (Panax quinquefolius L.) extract on glycemic control and cardiovascular risk factors in individuals with type 2 diabetes: a double-blind, randomized, cross-over clinical trial

Vuksan, V. V. V., Xu, Z. Z., Jovanovski, E., Jenkins, A. L., Beljan‐Zdravkovic, U., Sievenpiper, J. L., Stavro, P. M., Zurbau, A., Duvnjak, L. S., & Li, M. Z. C. (2018) · European Journal of Nutrition · doi:10.1007/s00394-018-1642-0 · Cited by 85 · see citing works

Short-Term Global Cardiovascular Disease Risk Prediction in Older Adults

Saeed, A., Nambi, V., Sun, W., Virani, S. S., Taffet, G. E., Deswal, A. M., Selvin, E., Matsushita, K., Wagenknecht, L. E., Hoogeveen, R. C., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.02.050 · Cited by 85 · see citing works

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

Seko, Y., Nishikawa, T., Umemura, A., Yamaguchi, K., Moriguchi, M., Yasui, K., Kimura, M., Iijima, H., Hashimoto, T., Sumida, Y., et al. (2018) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s184767 · Cited by 80 · see citing works

The Pleiotropic Effects of Sodium–Glucose Cotransporter-2 Inhibitors: Beyond the Glycemic Benefit

Patel, D. K., & Strong, J. L. (2019) · Diabetes Therapy · doi:10.1007/s13300-019-00686-z · Cited by 79 · see citing works

Therapeutic medications against diabetes: What we have and what we expect

Hu, C., & Jia, W. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.11.008 · Cited by 80 · see citing works

Learning Physiology from Inherited Kidney Disorders

van der Wijst, J., Belge, H., Bindels, R. J. M., & Devuyst, O. (2019) · Physiological Reviews · doi:10.1152/physrev.00008.2018 · Cited by 76 · see citing works

Pair Feeding, but Not Insulin, Phloridzin, or Rosiglitazone Treatment, Curtails Markers of β-Cell Dedifferentiation in db/db Mice

Ishida, E., Kim-Muller, J. Y., & Accili, D. (2017) · Diabetes · doi:10.2337/db16-1213 · Cited by 76 · see citing works

A Systematic Review of Newer Antidiabetic Agents in the Treatment of Nonalcoholic Fatty Liver Disease

Dougherty, J. A., Guirguis, E. H., & Thornby, K. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020935105 · Cited by 74 · see citing works

Marein ameliorates diabetic nephropathy by inhibiting renal sodium glucose transporter 2 and activating the AMPK signaling pathway in db/db mice and high glucose–treated HK-2 cells

Guo, Y., Ran, Z., Zhang, Y., Song, Z., Wang, L., Yao, L., Zhang, M., Xin, J., & Mao, X. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110684 · Cited by 73 · see citing works

The effect of SGLT-2 inhibitors on albuminuria and proteinuria in diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Piperidou, A., Sarafidis, P., Boutou, A., Thomopoulos, C., Loutradis, C., Alexandrou, M. E., Tsapas, A., & Karagiannis, A. (2019) · Journal of Hypertension · doi:10.1097/hjh.0000000000002050 · Cited by 72 · see citing works

Efficacy and Safety of Mulberry Twig Alkaloids Tablet for the Treatment of Type 2 Diabetes: A Multicenter, Randomized, Double-Blind, Double-Dummy, and Parallel Controlled Clinical Trial

Qu, L., Liang, X., Tian, G., Zhang, G., Wu, Q., Huang, X., Cui, Y., Liu, Y., Shen, Z., Xiao, C., et al. (2021) · Diabetes Care · doi:10.2337/dc20-2109 · Cited by 72 · see citing works

Association between prediabetes and adverse outcomes in heart failure

Mai, L., Wen, W., Qiu, M. R., Liu, X., Sun, L., Zheng, H., Cai, X., & Huang, Y. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14490 · Cited by 70 · see citing works

Direct Blood Pressure-Independent Anti-Fibrotic Effects by the Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone in Progressive Models of Kidney Fibrosis

Droebner, K., Pavkovic, M., Grundmann, M., Hartmann, E., Goea, L., Nordlohne, J., Klar, J., Eitner, F., & Kolkhof, P. (2021) · American Journal of Nephrology · doi:10.1159/000518254 · Cited by 70 · see citing works

Endothelial Dysfunction in Heart Failure With Preserved Ejection Fraction: What are the Experimental Proofs?

Cornuault, L., Rouault, P., Duplàa, C., Couffinhal, T., & Renault, M. (2022) · Frontiers in Physiology · doi:10.3389/fphys.2022.906272 · Cited by 72 · see citing works

Sodium-glucose cotransporter-2 inhibitors (SGLT2) in frail or older people with type 2 diabetes and heart failure: a systematic review and meta-analysis

Aldafas, R., Crabtree, T. S. J., Alkharaiji, M. A., Vinogradova, Y., & IDRIS, I. R. (2023) · Age and Ageing · doi:10.1093/ageing/afad254 · Cited by 71 · see citing works

Dapagliflozin improves myocardial flow reserve in patients with type 2 diabetes: the DAPAHEART Trial: a preliminary report

Leccisotti, L., Cinti, F., Sorice, G. P., D’Amario, D., Lorusso, M., Guzzardi, M. A., Mezza, T., Gugliandolo, S., Cocchi, C., Capece, U., et al. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01607-4 · Cited by 68 · see citing works

Renal physiology of glucose handling and therapeutic implications

Cherney, D. Z. I., Kanbay, M., & Lovshin, J. A. (2019) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfz230 · Cited by 66 · see citing works

Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19

Rhee, S. Y., Lee, J.-W., Nam, H., Kyoung, D., Shin, D. W., & Kim, D. J. (2021) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2020.0206 · Cited by 63 · see citing works

Impact of sodium–glucose cotransporter 2 inhibitors on blood pressure

Reed, J. W. (2016) · Vascular Health and Risk Management · doi:10.2147/vhrm.s111991 · Cited by 65 · see citing works

2023 Guidelines on the management of patients with diabetes - a position of Diabetes Poland

Araszkiewicz, A., Bandurska-Stankiewicz, E. M., Borys, S., Budzynski, A. Z., Cyganek, K., Cypryk, K., Czech, A., Czupryniak, L., Drzewoski, J., Dzida, G. J., et al. (2023) · Current Topics in Diabetes · doi:10.5114/ctd/160061 · Cited by 65 · see citing works

Semaglutide and Cardiovascular Outcomes by Baseline HbA1c and Change in HbA1c in People With Overweight or Obesity but Without Diabetes in SELECT

Lingvay, I., Deanfield, J. E., Kahn, S. E., Weeke, P. E., Toplak, H., Scirica, B. M., Rydén, L., Rathor, N., Plutzky, J., Morales, C., et al. (2024) · Diabetes Care · doi:10.2337/dc24-0764 · Cited by 64 · see citing works

Obesity medications in development

Rebello, C. J., & Greenway, F. L. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1705277 · Cited by 62 · see citing works

Therapy of Type 2 Diabetes

Landgraf, R., Aberle, J., Birkenfeld, A. L., Gallwitz, B., Kellerer, M., Klein, H., Müller-Wieland, D., Nauck, M. A., Reuter, H.-M., & Siegel, E. (2019) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1018-9106 · Cited by 62 · see citing works

Empagliflozin attenuates trastuzumab-induced cardiotoxicity through suppression of DNA damage and ferroptosis

Min, J., Wu, L., Liu, Y., Song, G., Deng, Q., Wei, J. J., Yu, W., Abudureyimu, M., Pei, Z., & Ren, J. T. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.121207 · Cited by 61 · see citing works

Cardiovascular Protection by Sodium Glucose Cotransporter 2 Inhibitors: Potential Mechanisms

Staels, B. (2017) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2017.05.013 · Cited by 59 · see citing works

Dapagliflozin mitigates cellular stress and inflammation through PI3K/AKT pathway modulation in cardiomyocytes, aortic endothelial cells, and stem cell-derived β cells

Alsereidi, F. R., Khashim, Z., Marzook, H., Al-Rawi, A. M., Salomon, T., Almansoori, M. K., Madkour, M. M., Hamam, A. M., Ramadan, M. M., Peterson, Q. P., et al. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02481-y · Cited by 58 · see citing works

Canadian Cardiovascular Harmonized National Guidelines Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2018 update

Tobe, S. W., Stone, J. A., Anderson, T. J., Bacon, S., CHENG, A. Y. Y., Daskalopoulou, S. S., Ezekowitz, J. A., Grégoire, J. C., Gubitz, G. J., Jain, R., et al. (2018) · Canadian Medical Association Journal · doi:10.1503/cmaj.180194 · Cited by 57 · see citing works

Acute kidney injury in diabetic patients: A narrative review

Kaur, A., Sharma, G. S., & Kumbala, D. R. (2023) · Medicine · doi:10.1097/md.0000000000033888 · Cited by 66 · see citing works

Mechanisms of SGLT2 Inhibitors in Heart Failure and Their Clinical Value

Xie, Y., Wei, Y., Li, D., Pu, J., Ding, H., & Zhang, X. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001380 · Cited by 58 · see citing works

Low-Dose Empagliflozin Improves Systolic Heart Function after Myocardial Infarction in Rats: Regulation of MMP9, NHE1, and SERCA2a

Goerg, J., Sommerfeld, M., Greiner, B., Lauer, D., Seckin, Y., Kulikov, A. N., Ivkin, D. Y., Kintscher, U., Okovityi, S. V., & Kaschina, E. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115437 · Cited by 53 · see citing works

Practical Approach to Initiating SGLT2 Inhibitors in Type 2 Diabetes

Peralta, F. G., Abreu, C., Lecube, A., Bellido, D., Soto, A., Morales, C., Brito-Sanfiel, M. Á., & Umpierrez, G. E. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0277-0 · Cited by 52 · see citing works

Utilizing mobile technologies to improve physical activity and medication adherence in patients with heart failure and diabetes mellitus: Rationale and design of the TARGET-HF-DM Trial

Sharma, A., Mentz, R. J., Granger, B. B., Heitner, J. F., Cooper, L. B., Banerjee, D., Green, C. L., Majumdar, M. D., Eapen, Z. J., Hudson, L. L., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.01.007 · Cited by 51 · see citing works

Effect of Empagliflozin on Cardiac Function, Adiposity, and Diffuse Fibrosis in Patients with Type 2 Diabetes Mellitus

Hsu, J., Wang, C., Su, M.-Y. M., Lin, L., & Yang, W. (2019) · Scientific Reports · doi:10.1038/s41598-019-51949-5 · Cited by 52 · see citing works

Epicardial Fat Expansion in Diabetic and Obese Patients with Heart Failure and Preserved Ejection Fraction—A Specific HFpEF Phenotype

Elsanhoury, A., Nelki, V., Kelle, S., Van Linthout, S., & Tschöpe, C. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.720690 · Cited by 51 · see citing works

Reinterpreting Cardiorenal Protection of Renal Sodium–Glucose Cotransporter 2 Inhibitors via Cellular Life History Programming

Avogaro, A., Fadini, G. P., & Prato, S. D. (2019) · Diabetes Care · doi:10.2337/dc19-1410 · Cited by 50 · see citing works

Effects of SGLT-2 inhibitors on adipose tissue distribution in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials

Wang, X., Wu, N., Sun, C., Jin, D., & Lu, H. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01085-y · Cited by 50 · see citing works

Effects of sodium‐glucose cotransporter‐2 inhibitors on the cardiovascular and renal complications of type 2 diabetes

CHILTON, R. J. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13854 · Cited by 50 · see citing works

Beta-Hydroxybutyrate, Friend or Foe for Stressed Hearts

Chu, Y., Zhang, C., & Xie, M. (2021) · Frontiers in Aging · doi:10.3389/fragi.2021.681513 · Cited by 52 · see citing works

Sodium-Glucose Co-transporter 2 (SGLT2) Inhibitor: Comparing Trial Data and Real-World Use

McGovern, A. P., Feher, M. D., Munro, N. M., & de Lusignan, S. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0254-7 · Cited by 49 · see citing works

Characterization and comparison of SGLT2 inhibitors: Part 3. Effects on diabetic complications in type 2 diabetic mice

Tahara, A., Takasu, T., Yokono, M., Imamura, M., & Kurosaki, E. (2017) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2017.05.019 · Cited by 49 · see citing works

Effect of Sodium Glucose Cotransporter 2 Inhibitors With Low SGLT2/SGLT1 Selectivity on Circulating Glucagon-Like Peptide 1 Levels in Type 2 Diabetes Mellitus

Takebayashi, K., & Inukai, T. (2017) · Journal of Clinical Medicine Research · doi:10.14740/jocmr3112w · Cited by 49 · see citing works

SGLT2 inhibition and glucagon secretion in humans

Saponaro, C., Pattou, F. N., & Bonner, C. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.06.005 · Cited by 49 · see citing works

Canadian Cardiovascular Harmonized National Guideline Endeavour (C-CHANGE) guideline for the prevention and management of cardiovascular disease in primary care: 2022 update

Jain, R., Stone, J. A., Agarwal, G., Andrade, J. G., Bacon, S., BAJAJ, H. S., Baker, B., Cheng, G., Dannenbaum, D. A., Gelfer, M., et al. (2022) · Canadian Medical Association Journal · doi:10.1503/cmaj.220138 · Cited by 48 · see citing works

Competing Effects of Renin Angiotensin System Blockade and Sodium-Glucose Cotransporter-2 Inhibitors on Erythropoietin Secretion in Diabetes

Marathias, K. P., Lambadiari, V., Markakis, K. P., Vlahakos, V., Bacharaki, D., Raptis, A. E., Dimitriadis, G., & Vlahakos, D. (2020) · American Journal of Nephrology · doi:10.1159/000507272 · Cited by 47 · see citing works

Podocyte Glucocorticoid Receptors Are Essential for Glomerular Endothelial Cell Homeostasis in Diabetes Mellitus

Srivastava, S. P., Zhou, H., Setia, O., Dardik, A., Fernandez-Hernando, C. F., & Goodwin, J. E. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019437 · Cited by 47 · see citing works

2018 ESC/ESH Guidelines for the management of arterial hypertension

Williams, B., Mancia, G., Spiering, W., Rosei, E., Azizi, M., Burnier, M., Clement, D., Coca, A., de Simone, G., Dominiczak, A. F., et al. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2018.12.005 · Cited by 47 · see citing works

Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved

Coats, A. J. S., Butler, J., Tsutsui, H., Doehner, W., Filippatos, G. S., Ferreira, J. P., Böhm, M., Chopra, V., Verma, S., Nordaby, M., et al. (2023) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13393 · Cited by 46 · see citing works

Loss of Mitochondrial Control Impacts Renal Health

Srivastava, S. P., Kanasaki, K., & Goodwin, J. E. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.543973 · Cited by 46 · see citing works

Empagliflozin prevents from early cardiac injury post myocardial infarction in non-diabetic mice

Liu, Y., Wu, M., Xu, J., Xu, B., & Kang, L. (2021) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2021.105788 · Cited by 46 · see citing works

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Baglioni, P. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1902837 · Cited by 316 · see citing works

Cardiovascular Outcomes and Safety of Empagliflozin in Patients With Type 2 Diabetes Mellitus and Peripheral Artery Disease: A Subanalysis of EMPA-REG OUTCOME

Verma, S., Mazer, C. D., Al-Omran, M., Inzucchi, S. E., Fitchett, D., Hehnke, U., George, J. T., & Zinman, B. (2018) · Circulation · doi:10.1161/circulationaha.117.032031 · Cited by 166 · see citing works

Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes mellitus. Dr. Hertzel Gerstein in an interview with Dr. Roman Jaeschke

Gerstein, H. C., & Jaeschke, R. (2016) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.3612 · Cited by 3 · see citing works

Empagliflozin reduces cardiovascular events and mortality in type 2 diabetes

Guthrie, R. M. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1174566 · Cited by 3 · see citing works

Reducing type 2 diabetes mortality: empagliflozin study

Pezalla, E. J. (2015) · Healthcare executive